Update on the Prescription Stimulant Shortage
Dear Americans,
On August 1, 2023, I wrote to you with FDA Commissioner Robert Califf to address the lack of availability of certain prescription stimulant medications. As we said then, the U.S. Food and Drug Administration (FDA)and the Drug Enforcement Administration (DEA) recognize the important role that prescription stimulants play in the treatment of conditions such as attention-deficit/hyperactivity disorder (ADHD), binge eating disorder, and narcolepsy. I am writing to you now to provide an update on the actions the DEA has taken, and is taking, to address shortages.
DEA Fentanyl Seizures in 2023
The 2023 fentanyl seizures represent over 332.6 million deadly doses. *
Featured
DEA Executes Operation Bottleneck
Today, the U.S. Drug Enforcement Administration announced administrative actions against six DEA-registered companies which, together, failed to account for more than a million doses of opioids.
Read about Operation Bottleneck
DEA Adds Precursor Chemicals to Special Surveillance List
The DEA has updated the Special Surveillance List (SSL) to include precursor chemicals and lab equipment often used in the illicit manufacture of fentanyl, fentanyl-related substances, meth, and other synthetic drugs.
Read the Special Surveillance List